Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL… Read full Trend Edge analysis →
| Current Price | $20.21 |
|---|---|
| Market Cap | $2.99B |
| Float | 144.3M |
| Shares Outstanding | 158.7M |
| Price/Sales (TTM) | 3,643.65 |
| vs. Analyst Target | +75.3% to analyst PT |
| Dividend Rate | None |
| Analyst Target Price | $35.43 (19 analysts) |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2020 | $336M | $71.1M | $336M | $71.2M |
| 2021 | $48.7M | -$291M | $48.7M | -$287M |
| 2022 | $108M | -$326M | $108M | -$330M |
| 2023 | $331M | -$145M | $331M | -$180M |
| 2024 | N/A | -$423M | -$7.8M | -$493M |
| 2025 | N/A | -$513M | -$11.2M | -$498M |
| Quarter | Revenue | Net Income |
|---|---|---|
| Jun 2025 | N/A | -$124M |
| Sep 2025 | N/A | -$127M |
| Dec 2025 | N/A | -$129M |
| Mar 2026 | N/A | -$128M |
| Insider Ownership | 9.1% |
|---|---|
| Institutional Ownership | 99.5% |
| Short Float | 10.3% |
| % of All Funds Holding | 2.96% |
| Number of Funds Holding | 243 |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $19.39 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $18.04 | Medium-term trend |
| Weekly | 80-Week SMA | $17.59 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $21.96 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $18.31 | Near-term monthly trend |
| Monthly | 20-Month SMA | $18.28 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $20.57 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Volume shelf data not available.
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | -0.23% | -0.02% | 50.00% | 9.58% | -5.61% |
| 1 Day | -1.11% | -1.40% | 41.18% | 13.97% | -15.06% |
| 1 Week | -1.49% | -3.65% | 29.41% | 24.68% | -18.83% |
| 2 Weeks | -1.16% | -4.35% | 38.24% | 24.91% | -18.55% |
| 1 Month | 0.84% | -1.20% | 48.48% | 46.03% | -33.92% |
Next earnings: July 26, 2026 (59 days away)
| Month | Avg Return | Win Rate | Samples |
|---|---|---|---|
| Jan | 6.9% | 55.6% | 9 |
| Feb | -2.3% | 33.3% | 9 |
| Mar | -8.8% | 22.2% | 9 |
| Apr | 0.8% | 55.6% | 9 |
| May | 4.7% | 75.0% | 8 |
| Jun | 6.0% | 62.5% | 8 |
| Jul | -4.6% | 37.5% | 8 |
| Aug | 6.7% | 62.5% | 8 |
| Sep | 2.2% | 50.0% | 8 |
| Oct | -3.7% | 37.5% | 8 |
| Nov | 13.7% | 62.5% | 8 |
| Dec | 1.1% | 37.5% | 8 |
| Day | Avg Return | Win Rate | Samples |
|---|---|---|---|
| Monday | -0.05% | 45.6% | 397 |
| Tuesday | 0.35% | 52.4% | 439 |
| Wednesday | 0.29% | 50.7% | 434 |
| Thursday | -0.26% | 44.3% | 427 |
| Friday | 0.04% | 47.5% | 427 |
Institutional holder breakdown coming soon.
Total institutional ownership: 99.5%
Total insider ownership: 9.1%
Founder-led management: Ryan Watts (Co-Founder, President, CEO & Director), Alexander Schuth (Co-Founder, CFO, COO & Secretary)
| Total Filings | 5 |
|---|---|
| Net Value | -$7.9M |
| Net Shares Change | -59,096 |
| % of Float | -0.0% |
| C-Suite Filings | 5 |
| Clusters Detected | 0 |
| Name | Title | Net Value | Filings | Activity |
|---|---|---|---|---|
| Watts Ryan J. | President and CEO | -$7.5M | 2 | 1 sell |
| Schuth Alexander O. | COFO and Secretary | -$323,981.46 | 2 | 2 sell |
| Ho Carole | Chief Medical Officer | -$51,684.467 | 1 | N/A |
| Date | Insider | Title | Net Value | Price After |
|---|---|---|---|---|
| 2026-01-08 | Schuth Alexander O. | COFO and Secretary | -$284,097 | Transaction at $16.50, now +22.5% |
| 2026-01-08 | Watts Ryan J. | President and CEO | -$580,767 | Transaction at $16.50, now +22.5% |
| 2025-08-14 | Schuth Alexander O. | COFO and Secretary | -$39,884.46 | Transaction at $13.58, now +48.8% |
| 2025-07-11 | Watts Ryan J. | President and CEO | -$6.9M | Transaction at $8.03, now +151.8% |
| 2025-08-14 | Ho Carole | Chief Medical Officer | -$51,684.467 | Transaction at $13.81, now +46.4% |
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Denali Therapeutics Inc (DNLI) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for DNLI on Trend Edge →